^
    Back
    Association details:
    Biomarker:KRAS G12A
    Cancer:Non Small Cell Lung Cancer
    Drug:Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Clin Lung Cancer
    Title:

    Preliminary safety, pharmacokinetics, and efficacy of regorafenib, cisplatin, and pemetrexed in patients with advanced non-squamous non-small cell lung cancers

    Excerpt:
    Regorafenib had acceptable tolerability and minor PK interactions in combination with standard doses of cisplatin and pemetrexed in patients with advanced nsNSCLCs. Encouraging activity was appreciated in chemotherapy-naive patients with advanced nsNSCLCs....Summary of treatment and outcomes to study treatment
    Secondary therapy:
    cisplatin + pemetrexed RTD
    DOI:
    10.1016/j.cllc.2015.04.003